Sarah Cannon Research Institute at HealthOne

Denver, Colorado 82018

29 studies enrolling now · 91 studies all time

What they study most

Abdominal Neoplasm, Acinar Cell Carcinoma, Acinic Cell Tumor, Acute Myeloid Leukemia, Adenoid Cystic Carcinoma, Advance Solid Tumors, Advanced Cancer, Advanced Endometrial Carcinoma, Advanced Epithelioid Sarcoma, Advanced Gastric Carcinoma, Advanced Lymphoma, Advanced Malignancies

Studies at this site

• Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors — Recruiting now
• A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors — Recruiting now
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors — Recruiting now
• SMP-3124LP in Adults With Advanced Solid Tumors — Recruiting now
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors — Recruiting now
• A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors — Recruiting now
• Phase 1 Study of PF-08046033 in Advanced Solid Tumors — Recruiting now
• A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) — Recruiting now
• First In Human Study of CX-2051 in Advanced Solid Tumors — Recruiting now
• A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers — Recruiting now
• A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer — Recruiting now
• Study of HLD-0915 in Patients With Metastatic Prostate Cancer — Recruiting now
• A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors — Recruiting now
• A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types — Recruiting now
• Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors — Recruiting now
• MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors — Recruiting now
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors — Recruiting now
• Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors — Recruiting now
• A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors — Recruiting now
• A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) — Recruiting now
• Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors — Recruiting now
• Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors — Recruiting now
• A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors — Recruiting now
• JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors — Recruiting now
• A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. — Recruiting now
• A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors — Recruiting now
• This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors — Recruiting now
• Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 — Recruiting now
• Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors — Completed
• A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies — Running, not enrolling
• A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors — Completed
• First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer — Running, not enrolling
• A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) — Completed
• A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) — Completed
• A Study of CS231295 in Patients With Advanced Solid Tumors — Starting soon
• Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas — Completed
• A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies — Stopped early
• A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) — Running, not enrolling
• Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors — Stopped early
• A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer — Stopped early
• P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors — Running, not enrolling
• Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma — Stopped early
• M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) — Stopped early
• A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors — Running, not enrolling
• Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression — Running, not enrolling
• Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies — Running, not enrolling
• Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies — Stopped early
• A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors — Stopped early
• A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors — Stopped early
• CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma — Completed